ESSA Pharma (EPIX) Competitors

Arcturus Therapeutics (NASDAQ:ARCT) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Which has higher valuation & earnings, ARCT or EPIX?

ESSA Pharma has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$152.31M	3.47	-$80.94M	-$2.23	-8.74
ESSA Pharma	N/A	N/A	-$28.54M	-$0.56	-3.45

Does the media prefer ARCT or EPIX?

In the previous week, Arcturus Therapeutics had 32 more articles in the media than ESSA Pharma. MarketBeat recorded 37 mentions for Arcturus Therapeutics and 5 mentions for ESSA Pharma. ESSA Pharma's average media sentiment score of 1.13 beat Arcturus Therapeutics' score of 0.45 indicating that ESSA Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	4 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
ESSA Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ARCT or EPIX?

Arcturus Therapeutics presently has a consensus price target of $50.00, indicating a potential upside of 156.67%. ESSA Pharma has a consensus price target of $2.00, indicating a potential upside of 3.63%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Arcturus Therapeutics is more favorable than ESSA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
ESSA Pharma	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is ARCT or EPIX more profitable?

ESSA Pharma has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -49.26%. ESSA Pharma's return on equity of -21.71% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-49.26%	-24.87%	-17.75%
ESSA Pharma	N/A	-21.71%	-21.22%

Do institutionals and insiders have more ownership in ARCT or EPIX?

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 15.5% of ESSA Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has more risk and volatility, ARCT or EPIX?

Arcturus Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Summary

Arcturus Therapeutics beats ESSA Pharma on 9 of the 15 factors compared between the two stocks.